Back
Enanta Pharmaceuticals 10K Form
Sell
25
ENTA
Enanta Pharmaceuticals
Last Price:
9.30
Seasonality Move:
15.66%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-08 | 10Q | ENTA/Enanta Pharmaceuticals Quarterly |
| 2024-02-08 | 10Q | ENTA/Enanta Pharmaceuticals Quarterly |
| 2023-08-08 | 10Q | ENTA/Enanta Pharmaceuticals Quarterly |
| 2023-05-09 | 10Q | ENTA/Enanta Pharmaceuticals Quarterly |
| 2023-02-08 | 10Q | ENTA/Enanta Pharmaceuticals Quarterly |
| 2022-08-08 | 10Q | ENTA/Enanta Pharmaceuticals Quarterly |
Receive ENTA News And Ratings
See the #1 stock for the next 7 days that we like better than ENTA
ENTA Financial Statistics
Sales & Book Value
| Annual Sales: | $79.2M |
|---|---|
| Cash Flow: | $-21.32M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $7.03 |
| Price / Book: | 1.36 |
Profitability
| EPS (TTM): | -5.45000 |
|---|---|
| Net Income (TTM): | $-115.33M |
| Gross Margin: | $0 |
| Return on Equity: | -59.98% |
| Return on Assets: | -26.23% |
Enanta Pharmaceuticals Earnings Forecast
Key Enanta Pharmaceuticals Financial Ratios
- The Gross Profit Margin over the past 4 years for ENTA is 0.00%.
- The Selling, General & Administrative Expenses for ENTA have been equal to 66.77% of Gross Profit Margin.
- The Research & Development expenses have been 206.46% of Revenue.
- The Interest Expense is -3.85% of Operating Income.
- The Net Earning history of ENTA is -168.95% of Total Revenues.
- Per Share Earnings over the last 14 years have been positive in 4 years.
Enanta Pharmaceuticals Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | ENTA |
| CUSIP: | 29251M |
| Website: | enanta.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 4.92 |
| Quick Ratio: | 4.65 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
ENTA Technical Analysis vs Fundamental Analysis
Sell
25
Enanta Pharmaceuticals (ENTA)
is a Sell
Is Enanta Pharmaceuticals a Buy or a Sell?
-
Enanta Pharmaceuticals stock is rated a Sell
The current Enanta Pharmaceuticals [ENTA] share price is $9.08. The Score for ENTA is 25, which is 50% below its historic median score of 50, and infers higher risk than normal.